Analysts buzz over new Amgen CEO’s plans for $20B cache

In the 18 months ahead of his recent departure from the top R&D post at Amgen ($AMGN), Roger Perlmutter helped execute at least three new deals: Committing up to a billion dollars to buy BioVex and bring in the cancer cell-killing virus it engineered; snagging Micromet in a $1.
Read the full story: News